السويد - السويدية - Läkemedelsverket (Medical Products Agency)

trichopharma ab - trichophyton verrucosum, stam bodin 1902, levande försvagad - pulver och vätska till injektionsvätska, suspension - trichophyton verrucosum, stam bodin 1902, levande försvagad 3125000 - 18750000 cfu aktiv substans; sackaros hjälpämne - trikofyton (ringorm) - nöt

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

bifodan a/s - bifidobacterium longum; lactobacillus rhamnosus, 271 - enterokapsel, hård - lactobacillus rhamnosus, 271 7 log10 cfu aktiv substans; bifidobacterium longum 7 log10 cfu aktiv substans; glukos (vattenfri) hjälpämne - mikroorganismer

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

axellus a/s - lactobacillus gasseri, dsm14869; lactobacillus rhamnosus, dsm 14870 - vaginalkapsel, hård - laktitolmonohydrat hjälpämne; lactobacillus rhamnosus, dsm 14870 8 log10 cfu aktiv substans; lactobacillus gasseri, dsm14869 8 log10 cfu aktiv substans; glukos (vattenfri) hjälpämne - exkl. kombinationer med kortikosteroider

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

bioveta a.s. - trichophyton verrucosum, stam bodin 1902, levande försvagad - pulver och vätska till injektionsvätska, suspension - sackaros hjälpämne; trichophyton verrucosum, stam bodin 1902, levande försvagad 3125000 - 18750000 cfu aktiv substans - nöt

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

intervet international b.v. - bordetella bronchiseptica, stam b-c2, levande; hundparainfluensavirus (cpiv), stam cornell, levande försvagat - frystorkat pulver och vätska till näsdroppar, suspension - sorbitol hjälpämne; hundparainfluensavirus (cpiv), stam cornell, levande försvagat 3 - 5,8 log10 tcid50 aktiv substans; bordetella bronchiseptica, stam b-c2, levande 8 - 9,7 log10 cfu aktiv substans - levande bakteriella och virala vacciner - hund

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

pharmaxis europe limited - mannitol - cystisk fibros - hosta och kalla preparat - bronchitol är indicerat för behandling av cystisk fibros (cf) hos vuxna 18 år och äldre som tilläggsbehandling till bästa vårdstandard.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystisk fibros - andra andningsorganprodukter - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 och 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 och 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystisk fibros - andra andningsorganprodukter - orkambi tabletter är indicerat för behandling av cystisk fibros (cf) hos patienter i åldern 6 år och äldre och som är homozygot för den f508del mutation i cftr-genen. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystisk fibros - andra andningsorganprodukter - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.